Arbutus Biopharma Corp
Arbutus Biopharma Corp (ABUS) Covered Calls
Arbutus Biopharma Corp trades in the Biotechnology industry with an IV Rank of 83.33%, high versus the past year. ABUS's highest covered call setup is the $5.50 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 35.14% out of the money with 57 days to expiration, a 36.36% return until expiration, and a 232.85% theoretical annualized return. Across the setups shown, annualized returns run from 31.17% to 232.85% at strikes between $4.50 and $5.50, with 57 to 210 days to expiration, as of Nov 19, 2026.
Read more
Running ABUS covered calls helps you generate income from Arbutus Biopharma Corp shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ABUS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ABUS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ABUS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ABUS covered call is worth writing.
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
| 2027-01-15 | 57 | 5.50 | 35.14 | 0.05 | 1.20 | 148.00 | 36.36 | 232.85 | -1.23 | +0.45 | 622 | 1.15 |
| 2027-06-17 | 210 | 5.50 | 35.14 | 0.05 | 0.80 | 148.00 | 36.36 | 63.20 | -1.23 | +0.38 | 0 | 0.75 |
| 2027-06-17 | 210 | 5.00 | 22.85 | 0.30 | 1.50 | 123.00 | 30.22 | 52.53 | -7.37 | +0.54 | 216 | 1.20 |
| 2027-06-17 | 210 | 4.50 | 10.57 | 0.30 | 0.95 | 73.00 | 17.94 | 31.17 | -7.37 | +0.53 | 33 | 0.65 |
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank83.33% High
- Market cap (M$)616
- 52 weeks high-26.24%
- 52 weeks low14.86%
- Analyst recommendationStrong Buy
1.00 - Target price$5.50
36.82% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E3.59
- Future P/E—
- EPS (ttm)1.12
- EPS growth next 5 years—
As of Nov 20, 2026